An Ebola virus vaccine, rVSVΔG-ZEBOV-GP, provided 100% protection against Ebola in a prior phase 3 trial. A new study reports long-term safety data and shows that the vaccine induces an antibody response for at least 1 year.
First-hand accounts of the care that was delivered during the 2013-16 West African outbreak of Ebola virus disease provided impetus for these guidelines.
Two vaccines to prevent Ebola virus disease demonstrated immune responses at 1 month.
A small percentage of Ebola virus survivors have a novel retinal lesion as a result of the disease.
The number of suspected Ebola cases in the Democratic Republic of Congo has risen to 37.
A strategy of preemptive use of an AD26.ZEBOV followed by MVA-BN-Filo immunization schedule in at-risk populations may offer advantages over reactive use of single-dose vaccine regimens.
Changes in messenger RNA abundance proved to be a reliable means of predicting patient's chances of surviving Ebola virus disease.
A new vaccine for Ebola showed high efficacy in preventing the development of Ebola in clusters of people exposed to the virus, and protection was also conferred to those who were not vaccinated.
Liberia's Men's Health Screening Program for Ebola survivors successful in spite of complex challenges.
Virus is more likely to be found in male survivors older than 40, researchers report.
The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of a candidate vaccine that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Are Antibiotic Stewardship Programs the Antidote to Antibiotic Overuse?
- Better Detection and Treatment Needed for H pylori Infections in Children
- FDA Approves New Hepatitis B Vaccine for Adults
- Strategies for Preventing Antibiotic Resistance in Acne
- Oral HPV Prevalence Higher in Men With Concurrent Genital HPV
- Study Finds Burnout Occurs in Over Half of US Surgeons
- HPV Vaccine Linked to Lower Respiratory Papillomatosis Rates
- Novel Antifungal Agent for Treatment of Aspergillus flavus Infections
- Inappropriate Antibiotic Use for Acute Bronchitis Highest in Younger Adults
- ACP, CDC Provides Best Practice Advice on Hepatitis B Management